Standard Azithromycin Dosing

Approved

AAlexa Henderson

Standard Azithromycin Dosing is one of 2 therapeutic programs targeting Pre-Term. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pre-TermNot yet recruiting

Pre-TermApproved

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Pre-Term

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 2

Standard Azithromycin Dosing

AAlexa Henderson

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

ApprovedNot yet recruiting

Pre-Term

NCT07669207

Clinical

Trials by Indication[1]

Pre-Term1 trial

Extended Azithromycin Treatment in Peri-viable and Extremely Preterm Prelabor Rupture of Membranes: A Pilot Study

Not yet recruiting·AAlexa Henderson·Approved·NCT07669207·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard Azithromycin Dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard Azithromycin Dosing. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alexa Henderson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: AAlexa Henderson

Standard Azithromycin Dosing

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Pre-Term1 trial

References

Drug Info

Quick Facts

Related News